News
WASHINGTON (Reuters) -AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by ...
Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback